Abstract
Repression of cell cycle progression by tumor suppressors might provide a means for tumor therapy. Here we demonstrate that ectopic overexpression of the p16INK4/CDKN2 tumor suppressor from an adenovirus vector in various cell lines results in block of cell division and, subsequently, in a gradual reduction of the levels of the product of retinoblastoma susceptibility gene, pRb. Overexpression of p53 and p16INK4/CDKN2, but not p53 on its own, induces apoptotic death only in tumor cells. Simultaneous adenoviral transfer of p16 and p53 genes leads to inhibition of tumor growth in nude mice. These results suggest that combined delivery of two cooperating genes like p16 and p53 could be the basis for the development of a new strategy for cancer gene therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Rosenberg, S.A. et ai. Immunization of cancer patients using autologous cancer Cells modified by insertion of the gene for interleukin-2. Hum. Gene Ther. 3, 75–90 (1992).
Culver, K.W. et al. In vivo gene transfer with retroviral vector producer Cells for treatment of experimental brain tumors. Science 256, 1550–1552 (1992).
Zhang, Y. et al. Retroviral vector-mediated transduction of K-ras antisense RNA into human cancer Cells inhibits expression of the malignant phenotype. Hum. Gene Ther. 4, 451–460 (1993).
Friedmann, T. Gene therapy of cancer through restoration of tumor-suppressor functions? Cancer 70 (Suppl.), 1810–1817 (1992).
Mulligan, R.C. The basic science of gene therapy. Science 260, 926–932 (1993).
Kremer, E.J. & Perricaudet, M. Adenovirus and adeno-associated virus mediated gene transfer. British Med. Bull. 51, 31–44 (1995).
Kozarsky, K.F. & Wilson, J.M. Gene therapy: Adenovirus vectors. Curr. Opin. Cen. Dev. 3, 499–503 (1993).
Kass-Eisler, A. et al. The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer. Gene Therapy 1, 395–402 (1994).
Huard, J. et al. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Therapy 2, 107–115 (1995).
Herz, J. & Gerard, R.D. Adenovirus-mediated low-density-lipoprotein receptor gene transfer accelerated cholesterol clearance in normal mice. Proc. Natl. Acad. Sd. USA 90, 2812–281 6 (1993).
Liu, T.-J. et al. Growth suppression of human head and neck cancer Cells by the introduction of a wild-type pS3 gene via a recombinant adenovirus. Cancer Res. 54, 3662–3667 (1994).
Zhang, W.-W. et al. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer Cells mediated by recombinant adenovirus. Cancer Gene Ther. 1, 1–10 (1994).
Clayman, G.L. et al. In vivo molecular therapy with p53 adenovirus for micror scopic residual head and neck squamous carcinoma. Cancer Res. 55, 1–6 (1995).
Weinberg, R.A. The retinoblastoma protein and Cell cycle control. Cell 81, 323–330 (1995).
Strauss, M., Lukas, J. & Bartek, J., Unrestricted Cell cycling and cancer. Nature Med. 1, 1245–1246 (1995).
Sheer, C.J. & Roberts, J.M. Inhibitors of mammalian Gl cyclin-dependent ki-nases. Genes Dev. 9, 1149–1163 (1995).
He, A. et al. CDK4 amplification is an alternative mechanism to p16 gene ho-mozygous deletion in glioma Cell lines. Cancer Res. 54, 5804–5807 (1994).
Motukura, T. & Arnold, A. Cyclins and oncogenesis. Biochem. Biophys. Acta 1155, 63–78 (1993).
Bates, S. & Peters, G. Cyclin D1 as a Cellular protooncogene. Sem. Cancer Biol. 6, 73–82 (1995).
Kamb, A. et al. A Cell cycle regulator potentially involved in genesis of many tumor types. Science 264, 436–440 (1994).
Nobori, T. et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancer. Nature 368, 753–756 (1994).
Merlo, A. et al. 5'CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN/MTS1 in human cancers. Nature Med. 1, 686–692 (1995).
Ottersen, G.A., Kratzke, T.A., Coxon, A., Kim, Y.W. & Kaye, F.J. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wild-type RB. Oncogene 9 3375–378 (1994).
Okamoto, A. et al. Mutations and altered expression of p16INK4 in human cancer. Proc. Natl. Acad. Sd. USA 91, 11045–1049 (1994).
Aagaard, L. et al. Aberrations of p16INK4 and retinoblastoma tumor-suppressor genes occur in distinct sub-sets of human cancer Cell lines. Intl. J. Cancer 61, 115–20 (1995).
Elledge, S.J. et al. The p21 cdk-interacting protein cip1 is potent inhibitor of Gl cyclin-dependent kinases. Cell 75, 805–816 (1993)
Xiong, Y. et al. p21 is a universal inhibitor of cyclin kinases. Nature 366, 701–704 (1993).
Deng, C., Zhang, P., Harer, W.J., Elledge, S.J., & Leder, P., Mice lacking P21CIPI/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82, 675–684 (1995).
Jin, X., Nguyen, D., Zhang, W.-W., Kyritsis, A.P. & Roth, J.A. Cell cycle arrest and inhibition of tumor Cell proliferation by the p16INK4 gene mediated by an adenovirus vector. Cancer Res. 55, 3250–3252 (1995).
Yang, Z.-Y., Perkins, N.D., Ohno, T., Nabel, E.G. & Nabel, G.J. The p21 cyclindependent kinase inhibitor suppresses tumorigenicity in vivo. Nature Med. 1, 1052–1056 (1995).
Eastham, J.A. et al. In vivo gene therapy with p53 or p21 and adenovirus for prostate cancer. Cancer Res. 55, 5151–5155 (1995).
Rowan, S. et al. Specific loss of apoptotic but not Cell cycle arrest function in a human tumour derived p53 mutant. EMBO J. 15, 827–838 (1996).
White, E., ife, death, and the pursuit of apoptosis. Genes Dev. 10, 1–15 (1996).
Roth, J.A. et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med. 2, 985–991 (1996)
Haas-Kogan, D.A. et al. Inhibition of apoptosis by the retinoblastoma gene product. EMB0 J. 14, 461–72 (1995).
Lukas, J. et al. Retinoblastoma-protein-dependent Cell-cycle inhibition by the tumour suppressor p16. Nature 375, 503–506 (1995).
Bates, S. & Vousden, K.H. . p53 in signaling checkpoint arrest or apoptosis. Curr. Opin. Cenet. Dev. 6, 12–19 (1996).
Gill, R.M. et al. Characterization of the human RBI promoter and of elements involved in transcriptional regulation. Cell Growth Diff. 5, 467–474 (1994).
An, B. & Dou, Q.P. Cleavage of retinoblastoma protein during apoptosis: An interleukin 1β-converting enzyme-like protease as candidate. Cancer Res. 56, 438–442 (1996).
Nevins, J.R. E2F: A link between the Rb tumor suppressor protein and viral onco-proteins. Science 258, 424–428 (1992).
Qin, X.-Q., Livingston, D.M., Kaelin, W.G. & Adams, P.D. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc. Notl. Acad. Sci. USA 91, 10918–10922 (1994).
Shan, B. & Lee, W.H. Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis. Mol. Cell Biol. 14, 8166–8173 (1994).
Wu, X. & Levine, A.J. . p53 and E2F-1 cooperate to mediate apoptosis. Proc. Natl. Acad. Sci. USA 91, 3602–3606 (1994).
Oltvai, Z.N., Miliman, C.L. & Korsmeyer, S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed Cell death. Cell 74, 609–619 (1993).
Miyashita, T. & Reed, J.C. Tumor suppressor p53 is a direct transcriptional activator of the human box gene. Cell 80, 293–299 (1995).
Yang, C., Cirielli, C., Capogrossi, M.C. & Passaniti, A. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor Cells. Cancer Res. 55, 4210–4213 (1995).
Bett, A.J., Haddara, W., Prevec, L. & Graham, F.L. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc. Natl. Acad. Sci. USA 91, 8802–8806 (1994).
McGrory, W.J., Bautista, D.S. & Graham, F.L. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology 163, 614–617 (1988).
Lieber, A., Sandig, V., Sommer, W., Bähring, S. & Strauss, M. Stable high-level gene expression in mammalian Cells by T7phage RNA polymerase. In Recombinant DNA Methodology II (ed. Wu, R.) 257–276 (Selected Meth. Enzymol., Academic Press, 1995).
Kanegae, Y., Makimura, M. & Saito, I. A simple and efficient method for purification of infectious recombinant adenovirus. Jpn. J. Med. Sci. Biol. 47, 157–166 (1994).
Carlsson, G., Gullberg, B. & Hafström, L. Estimation of liver tumor volume using different formulas — an experimental study in rats. J. Cancer Res. Clin. Oncol. 105, 20–23 (1983).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sandig, V., Brand, K., Herwig, S. et al. Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat Med 3, 313–319 (1997). https://doi.org/10.1038/nm0397-313
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nm0397-313
This article is cited by
-
Bicistronic transfer of CDKN2A and p53 culminates in collaborative killing of human lung cancer cells in vitro and in vivo
Gene Therapy (2020)
-
p53- and Bax-Mediated Apoptosis in Injured Rat Spinal Cord
Neurochemical Research (2011)
-
Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors
Cell Research (2006)
-
Gene Therapy Strategies for Hepatocellular Carcinoma
Journal of Biomedical Science (2006)
-
The tumor suppressor p16INK4a gene is a regulator of apoptosis induced by ultraviolet light and cisplatin
Oncogene (2004)
